Unfit individuals even have the alternative of venetoclax plus obinutuzumab (VO) as frontline therapy. This is based on the period III demo that compared VO with ClbO in elderly/unfit sufferers.113 VO was superior regarding response charge and progression-totally free survival, and had a similar safety profile. During this demo VO https://joshq530irz7.fare-blog.com/profile